Summary & Overview
HCPCS C9050: Injection, emapalumab-lzsg, 1 mg
HCPCS Level II code C9050 identifies the unit-dose injection of emapalumab-lzsg at 1 mg. Emapalumab-lzsg is a targeted biologic therapy used in specialized clinical settings; accurate coding with C9050 ensures standardized reporting of drug administration for billing and utilization tracking. Nationally, precise HCPCS coding for high-cost biologics affects payer coverage determinations, claims processing, and aggregate expenditure monitoring.
Key payers examined include Aetna, Blue Cross Blue Shield, Cigna, UnitedHealthcare, and Medicare. The publication provides a concise view of coding practices and payer coverage patterns relevant to C9050, highlighting what providers and billers need to reference when documenting emapalumab-lzsg injections.
Readers will learn: the clinical and service context for HCPCS Level II code C9050; typical sites of service for administration; payer coverage landscape across major national payers; and the types of benchmarks and policy updates that commonly affect biologic drug coding and reimbursement. Where input data is incomplete, the report clearly notes that specific fields are not available in the input. This summary is focused on national implications for coding consistency, billing workflows, and payer interactions for emapalumab-lzsg injections.
Billing Code Overview
HCPCS Level II code C9050 represents injection, emapalumab-lzsg, 1 mg. This code denotes the drug formulation and unit of service for emapalumab-lzsg administered by injection.
Service type: Medication injection (biologic therapy)
Typical site of service: Outpatient infusion or injection setting, including hospital outpatient departments and specialized infusion centers.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult or pediatric patient diagnosed with primary hemophagocytic lymphohistiocytosis (HLH) or another interferon-gamma–driven hyperinflammatory disorder who requires targeted cytokine blockade. The patient presents to an ambulatory infusion center, hospital outpatient infusion clinic, or inpatient unit for administration of C9050 (emapalumab-lzsg). Prior to treatment, the treating hematologist/oncologist or pediatric rheumatologist documents active disease with clinical and laboratory evidence (fever, cytopenias, hyperferritinemia, elevated soluble IL-2 receptor) and confirms weight-based dosing. Nursing performs medication verification, allergy check, and prepares the reconstituted vial; emapalumab is administered as an intravenous infusion by infusion nurse under direct physician or advanced practice provider oversight. Vital signs and infusion-related reactions are monitored during and after infusion; ancillary services (laboratory monitoring, supportive transfusions, antimicrobial prophylaxis) may be ordered per the clinician. Billing reflects drug supply per milligram using C9050 with units equal to milligrams administered and appropriate place-of-service coding for infusion center, outpatient hospital department, or inpatient administration.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug or biological amount discarded |